Liporex (Simvastatin)

• Simvastatin acts on the lipid metabolism pathway to manage cholesterol disorders and reduce cardiovascular risk.
• Hypercholesterolemia: lowers total and LDL cholesterol levels.
• Heterozygous familial hypercholesterolemia: improves lipid profile in genetically predisposed patients.
• Prevention of cardiovascular events: reduces incidence of heart attack and stroke in at‑risk individuals.

• Simvastatin is a pro‑drug that is converted in the liver to its active hydroxy acid form, which competitively inhibits HMG‑CoA reductase, the key enzyme in the mevalonate pathway of cholesterol synthesis. This inhibition decreases hepatic cholesterol production, up‑regulates LDL receptors on hepatocyte surfaces, and enhances clearance of circulating LDL particles, thereby lowering plasma cholesterol concentrations.

Simvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal upset: nausea, abdominal pain, or dyspepsia.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: mild transaminase increases.
• Dizziness: occasional light‑headedness.
• Fatigue: general tiredness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of kidney injury.
• Severe hepatic injury: marked elevation of liver enzymes or jaundice.
• Myopathy: muscle weakness with elevated CK levels.
• Allergic reactions: rash, pruritus, or angioedema.
• Hepatotoxicity: hepatitis or liver failure.
• Anaphylaxis: rare life‑threatening hypersensitivity.

• Before initiating therapy and during treatment, certain precautions should be observed.
• Assess liver function: obtain baseline hepatic enzyme tests.
• Monitor creatine kinase: check if muscle symptoms develop.
• Avoid use in active liver disease: contraindicated in patients with unexplained persistent elevations of transaminases.
• Use caution with grapefruit juice: it can increase simvastatin plasma concentrations.
• Review concomitant medications: assess for drugs that affect CYP3A4 metabolism.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Simvastatin interacts with several medicines that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may cause dangerous increases in simvastatin exposure.
• Gemfibrozil: significantly raises risk of myopathy and rhabdomyolysis.
• High‑dose niacin: enhances muscle toxicity.

Moderate Interactions (Monitor Closely)

• Amlodipine: may modestly increase simvastatin concentrations.
• Warfarin: requires INR monitoring due to potential anticoagulant effect alteration.